Pacira launches EXPAREL in the U.S.

Apr 9 2012

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced the commercial launch of EXPAREL^® (bupivacaine liposome injectable suspension) in the United States. Starting today, EXPAREL will begin shipping to hospital and ambulatory care customers through their normal wholesaler and distributor channels. EXPAREL was approved by the U.S. Food and Drug Administration (FDA) in October 2011 for administration into the surgical site to produce postsurgical analgesia.

Strong pre-launch commercialization efforts including more than 40 data publications and more than 1,700 interactions with potential customers have laid the groundwork for what Pacira believes will be the successful introduction of EXPAREL into the hospital marketplace.

"For Pacira, today is the culmination of several important organizational milestones that span the last several years, with the most significant being the FDA approval of EXPAREL," said Dave Stack, president and CEO of Pacira Pharmaceuticals. "For the millions of patients undergoing surgical procedures in the U.S. each year, the introduction of EXPAREL—a single-dose, non-opioid local analgesic given at the close of surgery—represents a significant addition to the armamentarium of currently available options to manage postsurgical pain."

The Pacira sales force, which consists of 63 hospital specialists who cover more than 81 percent of the market Pacira is targeting for EXPAREL, was launched in January 2012. Since that time, this team has been executing a formulary access strategy, working closely with key hospital and surgical customers to initiate the formulary review process to obtain access for EXPAREL.

"Through the work of our field force and the commercialization activities executed to date, awareness and anticipated demand for EXPAREL has continued to grow among our target markets," said Taunia Markvicka, PharmD, vice president, commercial. "We intend to build off that momentum through a targeted strategy in 2012 that encompasses Phase 4 clinical research, partnerships with key hospital customers and robust publication and medical education plans."